When exploring journal club a phase 3 randomized controlled trial of resmetirom in mash with liver fibrosis, it's essential to consider various aspects and implications. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with .... We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Journal Club: A Phase 3, Randomized, Controlled Trial of Resmetirom in .... Published in The New England Journal of Medicine in February 2024, this study provided the data that led to FDA approval of Resmetirom in March 2024 for adults with moderate to advanced...
Resmetirom Phase 3 Trial: Journal Club Review | MASLD COMMUNITY NETWORK. The phase 3 randomized controlled trial evaluated the efficacy of Resmetirom, the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. We are conducting this phase 3, double-blind, ran-domized, placebo-controlled trial at 245 sites in 15 countries.
The trial is ongoing and remains blinded to individual patient identification and trial-group assignments. First FDA-Approved NASH Treatment Produces NASH Resolution and .... Among patients with biopsy-proven MASH and liver fibrosis, resmetirom (both 80 mg and 100 mg doses) was superior to placebo regarding both histologic primary endpoints: improvement in MASLD activity score and fibrosis stage.
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 .... A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease. A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
To the Editor: Harrison et al. 8 issue) 1 found that resmetirom treatment reduced levels of free thyroxine (FT4) by approximately 16 to 19% in patients with nonalcoholic steatohepatitis... The first FDA approved medication for NASH is here! But what is the evidence supporting its use?
In this context, resmetirom for nonalcoholic fatty liver disease: a randomized, double .... MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo-controlled phase 3 trial evaluating the safety of resmetirom in adults with nonalcoholic fatty liver disease and presumed NASH.
📝 Summary
As demonstrated, journal club a phase 3 randomized controlled trial of resmetirom in mash with liver fibrosis represents an important topic worthy of attention. In the future, further exploration in this area will deliver more comprehensive insights and benefits.